Conference call to discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF will be held on November 13 at 4:30 pm. Webcast Link
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials
- Tenax Therapeutics reports Q3 EPS (40c), consensus ($1.12)
- TENX Earnings this Week: How Will it Perform?
- Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
- Tenax Therapeutics management to meet with Piper Sandler